Foundations

Sculptra, Radiesse, Ellansé and Juvelook: the biostimulator types explained

Dr Ong Jin Khang · MMC 45245 · LCP holder · The Retreat Clinic, Setia Alam

Sculptra (poly-L-lactic acid, PLLA), Radiesse (calcium hydroxylapatite, CaHA), Ellansé (polycaprolactone, PCL) and Juvelook (poly-D,L-lactic acid, PDLLA) each sit on a different material. All four are biostimulators: particles that ask the skin to build its own collagen, and none of them contains collagen. The effect builds over weeks to months, and published figures for how long it lasts start at about a year and run to two years or more, varying by material and by study. None of the four sets of particles can be dissolved with hyaluronidase, the enzyme a doctor can use to reverse hyaluronic acid filler after assessment, so the questions worth asking come before the first session.

A hand-drawn ink and watercolour cross-section of skin with a wooden lattice below the pink surface layer, green vines climbing it and small pale beads at the crossings, above a yellow fat layer. Illustration, not a photograph.

The name of the material says what was injected. The brand says who made it.

On this page
  1. What is a biostimulator, and is it a collagen injection?
  2. Which brand sits on which material?
  3. How long do biostimulators last?
  4. Can a biostimulator be dissolved?
  5. Do biostimulators help sagging skin?
  6. What to ask before any biostimulator

What is a biostimulator, and is it a collagen injection?

A biostimulator is an injected particle that prompts the skin to lay down new collagen as it is slowly absorbed. The US patient label for a PLLA product puts it plainly: the beads fill a wrinkle at first, and as they biodegrade the body may produce new collagen. A 2025 clinical guideline describes PLLA and PDLLA as provoking a sub-clinical inflammatory response, below the level of visible inflammation, that raises type I collagen at the injection site.

So collagen injection can mean two different things. Some fillers do contain collagen, and the FDA tells patients who are allergic to collagen to say so before treatment. A biostimulator contains none. Asking for the name of the material settles which is meant.

Which brand sits on which material?

Many of the names people search for sit on four materials, and a table that sets Sculptra and Juvelook beside RE20, Rejuran and Profhilo shows how those materials differ from boosters made of other things. Register entries, filed by the companies that hold them, and the published papers agree on which is which.

PLLA is the material in Sculptra: a man-made polymer also used in absorbable stitches, supplied as a dry powder and mixed with sterile water before injection. The FDA describes a series of injections over several months, with the effect becoming apparent over several weeks. The 2009 US label says the time it takes to resorb in humans is not known, and that in rabbits the particles were still visible more than a year after injection.

CaHA is the material in Radiesse: a mineral found in teeth and bones, made into microspheres 25 to 45 microns across and suspended in a gel of water, glycerin and carboxymethylcellulose. The gel gives fullness at once and is absorbed, while the microspheres stay and prompt collagen. CaHA shows up on X-ray and CT scans, which patients are told to mention to other doctors.

PCL is the material in Ellansé (often typed Ellanse) and Gouri. In Ellansé, PCL microspheres 25 to 50 microns across sit in a carboxymethylcellulose gel; a 2017 paper, most of whose authors consult for the maker, describes macrophages absorbing the gel over 6 to 8 weeks while the microspheres stimulate collagen. The register describes Gouri as a liquid form of PCL.

PDLLA is a close relative of PLLA: polylactic acid comes in two forms that differ in the arrangement of the molecule, the L form (PLLA) and the D,L form (PDLLA). AestheFill carries PDLLA in carboxymethylcellulose. The register describes Juvelook and Lenisna as PDLLA mixed with sodium hyaluronate, which it calls a carrier, and a 2025 laboratory comparison describes the Juvelook carrier as non-cross-linked hyaluronic acid. A 2024 consensus on one PDLLA product says clinical trials of PDLLA in aesthetic indications remain limited.

FeaturePLLA (Sculptra)CaHA (Radiesse)PCL (Ellansé, Gouri)PDLLA (AestheFill, Juvelook, Lenisna)
What it isA man-made polymer also used in absorbable stitchesA mineral found in teeth and bones, as microspheres in a gelPCL microspheres in a carboxymethylcellulose gelA close relative of PLLA, in carboxymethylcellulose or with hyaluronic acid
How long it lastsUp to 2 years (FDA); up to 25 months in a 2026 reviewAbout 18 months (FDA); 12 to 18 months in a 2026 reviewExpected 1, 2, 3 and 4 years for the four Ellansé versionsBrazilian consensus advises maintenance about every two years
Enzyme reversalPLLA nodules differ from HA nodules, which can respond to hyaluronidaseNo enzyme reverses CaHACannot be removed at once by an enzymeNodules do not respond to straightforward enzyme treatment
The four biostimulator materials compared, from figures measured in different ways, summarising the text and sources of this article.

How long do biostimulators last?

The figures below come from different sources and were measured in different ways, so they do not form a ranking. The FDA gives about 18 months for CaHA and up to 2 years for PLLA. A 2026 systematic review of 14 studies reported up to 25 months for PLLA and 12 to 18 months for CaHA. For PCL, the 2017 paper gives expected longevities of 1, 2, 3 and 4 years for the four Ellansé versions, and the 3 and 4 year figures are extrapolated rather than measured. A Brazilian expert consensus on one PDLLA product advises maintenance treatment about every two years.

The visible effect and the particle are different things. A 2024 review describes PDLLA and CaHA fillers as usually persisting for up to two years and, in individual patients, for more than five, broken down by hydrolysis and enzymes in the body. Several of the papers cited here disclose that their authors speak for, or consult to, makers or distributors.

Can a biostimulator be dissolved?

Not in the way hyaluronic acid filler can be. Hyaluronidase digests hyaluronic acid, and none of these four materials is hyaluronic acid. The published papers say so material by material: no enzyme reverses CaHA, PDLLA nodules do not respond to straightforward enzyme treatment, PCL fillers cannot be removed at once by an enzyme, and a 2026 scoping review separates PLLA nodules from nodules caused by HA, which can respond to hyaluronidase. The FDA puts it generally: fillers not made of HA can be difficult or impossible to remove.

Two qualifications. Where a product is mixed with HA, the enzyme can act on the HA but not on the particles: in a Brazilian series of 55 complications, hyaluronidase helped only where CaHA had been combined with HA. Whether it helps in a given case is for the doctor to judge. And for CaHA, sodium thiosulfate has been studied as a way to speed breakdown, but the 2024 review calls it slow-acting and not effective in an emergency.

What is done about a lump depends on its kind, and lumps are reported with each material. A 2026 review calls nodules one of the most frequently reported complications of CaHA, and says most palpable nodules are self-limiting and many soften over time; a 2020 series of PCL treatments describes nodules and granulomas as rare potential complications. Options include massage, breaking a lump up with a needle and saline or sterile water, injected medicines, antibiotics if infection is suspected, and surgical removal, and a lump that persists can need a prolonged course of treatment. Side effects from any filler can appear weeks, months or years after injection, and any filler can block a blood vessel, which the FDA highlights as the risk that can cause serious and sometimes lasting harm. How often lumps occur across the whole category is not known: a 2026 review protocol notes that no systematic review has yet covered adverse events across all the major biostimulators.

Do biostimulators help sagging skin?

My view is that biostimulators do help laxity. How much they help depends on where the skin starts. Severe laxity may improve too, but the expectation has to be managed.

The published evidence is modest, and the studies cited here concern only CaHA and PLLA. A 2017 pilot of diluted CaHA in 20 people with neck and décolleté laxity found more collagen on biopsy and better skin elasticity. A 2019 randomised trial of PLLA against saline for skin quality, in 40 women, reported increases in skin elasticity and hydration in the PLLA group at 12 months. A 2018 expert consensus describes diluted CaHA for laxity as an off-label use and says further trials will add clarity. Studies of this size cannot say how much a face with advanced laxity will improve. How laxity is assessed, and what else is used for it, is set out on the page on sagging skin and jawline laxity.

What to ask before any biostimulator

Which material is it, and which product? How is it prepared, and how deep does it go? What is the plan if a lump appears? Is there any health reason to wait? Active skin infection or inflammation at the site is a standard reason to defer, and the FDA notes that filler safety in pregnancy and breastfeeding is unknown. Ask, too, for the registration number and match it on the Medical Device Authority's register; the guide to checking an aesthetic doctor covers the rest.

How biostimulators sit beside PRP and microneedling is compared in three roads to collagen, and how far ahead a course needs to start is in collagen-building courses before an event.

A biostimulator is a slow decision, because the particles cannot be undone with an enzyme. It deserves a slow conversation first.

Common questions

What is the difference between Sculptra and Radiesse?

Sculptra is poly-L-lactic acid (PLLA), supplied as a dry powder and mixed with sterile water before injection. Radiesse is calcium hydroxylapatite (CaHA), microspheres in a gel that gives fullness at once. They are different materials with different preparation and time courses, and neither can be dissolved with hyaluronidase. The choice depends on the area, the skin and the aim.

Can Sculptra, Radiesse or Ellansé be dissolved?

No. Hyaluronidase digests hyaluronic acid, and PLLA, CaHA, PCL and PDLLA are not hyaluronic acid. A lump has to be managed instead, and a persistent one can need a prolonged course of treatment.

What are Juvelook, Lenisna and Gouri?

The Malaysian register describes Juvelook and Lenisna as PDLLA mixed with sodium hyaluronate, which it calls a carrier, and Gouri as a liquid form of PCL. They belong to the same broad class as Sculptra, Radiesse and Ellansé. Hyaluronidase may act on a hyaluronic acid carrier, but not on the PDLLA or PCL particles.

Sources

  1. US Food and Drug Administration. FDA-Approved Dermal Fillers. Content current as of 9 November 2020 Material descriptions and durations: CaHA (a mineral found in teeth and bones, particles in a gel, effects about 18 months, visible on X-ray); PLLA (man-made polymer used in absorbable stitches, series of injections over several months, effect increasingly apparent over several weeks, may last up to 2 years).
  2. US Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). Content current as of 7 June 2023 Fillers not made of HA may be difficult or impossible to remove; nodules or granulomas may need injections, oral antibiotics or surgical removal; side effects may appear weeks, months or years after injection; unintended injection into a blood vessel is the risk of most concern; some fillers contain collagen; pregnancy and breastfeeding safety unknown; inflamed or infected skin should wait.
  3. US patient labeling for a PLLA aesthetic implant, PMA P030050/S002 (2009) PLLA particles with carboxymethylcellulose, mannitol and sterile water; the beads fill at first and, as they biodegrade, the body may produce new collagen; gradual improvement over several weeks; the time to resorb in humans is not known and particles were visible in rabbits more than a year after injection.
  4. US instructions for use for a CaHA injectable implant, PMA P050052 (2006) CaHA in a gel carrier of sterile water, glycerin and sodium carboxymethylcellulose, particle size 25 to 45 microns; the particles are radiopaque and visible on CT and may be visible on plain X-ray; patients should tell other doctors and radiologists.
  5. Medical Device Authority, Malaysia. Malaysia Medical Device Register (MMDR), public search, entries opened 30 September 2026 (data updated 29 September 2026) Registered descriptions: Sculptra (PLLA microparticles, reconstituted from a dry powder with sterile water); Radiesse (CaHA suspended in a gel carrier; the gel is dissipated and replaced with soft tissue growth while the CaHA remains); Ellanse (PCL microspheres 25 to 50 microns in a gel carrier); Gouri (a fully solubilised liquid form of PCL); Juvelook and Lenisna (PLA, poly(D,L-lactide), lyophilised with HA, sodium hyaluronate, which the register calls a carrier to help inject the micro-particles; the register does not say the HA is non-cross-linked); AestheFill. All listed as medical devices.
  6. de Melo F, Nicolau P, Piovano L, Lin SL, et al. Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone-based collagen stimulator (Ellanse). Clin Cosmet Investig Dermatol 2017;10:431-440 PCL microspheres 25 to 50 microns in a carboxymethylcellulose gel; the gel is resorbed by macrophages in 6 to 8 weeks while the microspheres stimulate collagen; four versions with expected longevity of 1, 2, 3 and 4 years (L and E extrapolated); most authors consultants to the maker (disclosure read).
  7. Su CY, Chang YC, Cheng PJ, Fang HW. Comparative physicochemical characterization of polylactic acid-based dermal fillers. Polymers 2025;18(1):84 Polylactic acid is classified into PLLA and PDLLA by stereoisomeric structure; AestheFill, NeoFilera and Juvelook are PDLLA and Sculptra is PLLA; Juvelook carries the particles in non-cross-linked HA and the others in carboxymethylcellulose; the marketed longer-lasting biostimulatory fillers include Ellanse (30% PCL microspheres in a CMC gel) and Radiesse (30% CaHA microspheres in water, glycerin and CMC).
  8. Magacho-Vieira FN, Vieira AO, Soares A, Alvarenga HCL, et al. Consensus recommendations for the reconstitution and aesthetic use of poly-D,L-lactic acid microspheres. Clin Cosmet Investig Dermatol 2024;17:2755-2765 PDLLA microspheres (AestheFill) in carboxymethylcellulose; maintenance advised at biennial intervals; clinical trials of PDLLA aesthetic indications remain limited. Authors are speakers for a distributor (disclosure read).
  9. Magacho-Vieira FN, Ducati EPJ. Clinical management of poly-D,L-lactic acid nodules: a guideline with diagnostic and treatment flowchart. J Cosmet Dermatol 2025;24:e70158 PLLA and PDLLA induce a sub-clinical inflammatory tissue response that increases type I collagen at the injection site; PDLLA nodules do not respond to straightforward enzymatic treatment; massage, needle subcision with saline or sterile water, and surgical excision where a nodule persists.
  10. Sukmanskaya N, Cotofana S, Alfertshofer M. Complications of hyaluronic acid and calcium hydroxylapatite fillers: a comprehensive narrative review of clinical presentation and current management strategies. J Cosmet Dermatol 2026 For CaHA no enzymatic reversal is available; nodule formation is one of the most frequently reported CaHA complications, most palpable nodules are self-limiting and many soften over time; sodium thiosulfate evidence is anecdotal or preclinical.
  11. Lin SL, Christen MO. Polycaprolactone-based dermal filler complications: a retrospective study of 1111 treatments. J Cosmet Dermatol 2020;19:1907-1914 PCL-based fillers cannot be immediately removed by injection of an enzyme; nodules and granuloma described as rare potential complications (the single-clinician series itself recorded none, and 5 temporary palpable lumps in 1111 treatments; the article prints no rate or count).
  12. Flores Rodriguez JC, Porras Zamora BM, Rico Macias NM, Martinez LV, et al. The management of poly-L-lactic acid (PLLA) nodules: a scoping review and evidence-mapped clinical pathway. Cureus 2026;18:e110742 Nodules caused by HA are distinct in their potential for responding to hyaluronidase, unlike PLLA nodules. Authors are speakers for a maker (disclosure read).
  13. Wollina U, Goldman A. Spontaneous and induced degradation of dermal fillers: a review. J Cutan Aesthet Surg 2024;17:273-281 Hyaluronidase digests HA by cleaving the beta-1,4 glycosidic linkage; PDLLA and CaHA fillers are decomposed by hydrolysis and enzymes, usually persist up to 2 years and in single patients more than 5; sodium thiosulfate can stimulate CaHA degradation but is slow acting and not effective in an emergency.
  14. Ianhez M, de Goes E Silva Freire G, Sigrist RMS, Colpas PT, et al. Complications of collagen biostimulators in Brazil: description of products, treatments, and evolution of 55 cases. J Cosmet Dermatol 2024;23:2829-2835 In 55 cases hyaluronidase demonstrated efficacy only where there was an association with HA. (Product-level percentages are deliberately not used.)
  15. Ferreira ACM, Silva LR, Espasandin I, Sant'Anna JF, et al. Efficacy, durability, and safety of collagen biostimulators based on PLLA and CaHA in the face: a systematic review. Aesthet Plast Surg 2026;50:1291-1300 14 studies; PLLA maintained its effects for up to 25 months and CaHA 12 to 18 months; adverse effects mostly mild.
  16. Honnef LR, Coelho MS, Dias de Oliveira JM, Polmann H, et al. Proportion of adverse events of injectable collagen biostimulators after facial aesthetic treatment: a systematic review protocol. J Clin Med 2026;15(9):3182 No comprehensive systematic review has evaluated the proportion and nature of adverse effects across all major collagen biostimulators.
  17. Yutskovskaya YA, Kogan EA. Improved neocollagenesis and skin mechanical properties after injection of diluted calcium hydroxylapatite in the neck and decolletage: a pilot study. J Drugs Dermatol 2017;16:68-74 20 subjects with neck and decolletage laxity: more collagen I on biopsy at 4 and 7 months, better elasticity by cutometry.
  18. Bohnert K, Dorizas A, Lorenc P, Sadick NS. Randomized, controlled, multicentered, double-blind investigation of injectable poly-L-lactic acid for improving skin quality. Dermatol Surg 2019;45:718-724 40 women, PLLA against saline, three treatments 4 weeks apart: higher skin elasticity and hydration at 12 months (a trial of PLLA for improving skin quality, not a sagging trial; the abstract reports the increase in the PLLA-treated subjects, not a between-group difference).
  19. Goldie K, Peeters W, Alghoul M, Butterwick K, et al. Global consensus guidelines for the injection of diluted and hyperdiluted calcium hydroxylapatite for skin tightening. Dermatol Surg 2018;44 Suppl 1:S32-S41 An expert consensus that calls the use of diluted CaHA to improve laxity novel and off-label, and says further trials will provide additional clarity.
  20. Sohu and 21st Century Business Herald (Chinese-language media) on the nicknames 童颜针 and 少女针. Cited in the Chinese edition 童颜针 is used for polylactic acid products (PLLA or PDLLA) and 少女针 for PCL with CMC; a 2021 21jingji report (https://m.21jingji.com/article/20210629/herald/712cf842ca0ba8363b310868e7791b43_zaker.html) found clinics mixing the two names and one doctor calling 少女针 at times only a marketing wrapper.

Disclosure: Dr Ong is a certified trainer for IBSA, which makes Profhilo and Aliaxin, and received the 2025 IBSA Key Opinion Leader Award in September 2026. Dr Ong is a Sinclair accredited trainer for MAILI fillers, and in 2026 Sinclair, which also makes Ellansé, gave him its APAC KOL Trainer 2025 award and the clinic its MAILI Founding Partner Award. How he thinks about ties like these: The quiet we kept: what shapes what your doctor recommends.

If you need more information, you can always contact us.